SER-109 achieved statistically significant and clinically meaningful improvements in key primary and secondary efficacy measures compared with placebo –
– SER-109 was well tolerated, with a safety profile comparable to placebo –
– Company expects to finalize Biologics License Application (BLA) filing in mid-2022
https://finance.yahoo.com/news/england-journal-medicine-publishes-data-220100006.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.